Bicycle Therapeutics (BCYC) shares fell more than 31% in recent Friday trading after the company said topline data from a phase 1/2 trial of zelenectide pevedotin combined with Merck's (MRK) pembrolizumab showed a 60% overall response rate in first-line metastatic urothelial cancer, in-line with existing therapies.
The company said it plans to report dose selection and topline data from a phase 2/3 trial in H2 2025.
Bicycle also said treatment with zelenectide pevedotin alone in breast cancer patients with Nectin4 gene amplification showed "enhanced anti-tumor activity."
The company said it will advance its development strategy, including phase 1/2 trials in breast, lung, and multi-tumor cancers, starting in 2025.
Price: 13.77, Change: -6.35, Percent Change: -31.55
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。